Europe Leukemia Therapeutics Industry by disease condition (chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia, acute myeloid leukemia), by diagnosis (CT scan, biopsy, MRI), by treatments (chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant, stem cell therapy), by drugs (Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat), and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)
- Advertising -
According to the report Europe Leukemia Therapeutics Industry, published by Market Data Forecast, The Industry has been estimated at USD 1.51 Billion in 2016 and is projected to reach USD 2.26 Billion by 2021, at a CAGR of 8.4% during the forecast period from 2016 to 2021.
Leukemia is commonly caused due to the high exposure to radiations, unhealthy lifestyle, genetic factors, and environmental conditions. Leukemia cases are more common in adults and are observed to progress with aging.
It can be identified by the spread of the diseases and by the type of the blood cell that is affected.
- Advertising -
Browse Market data tables and in-depth TOC of the Europe Leukemia Therapeutics Industry to 2021 at www.marketdataforecast.com/market-…utics-market-824/
The Industry for Leukemia Therapeutics in Europe is propelling mainly due to factors like increased innovation and R&D in the oncology sectors and growing number of biotechnology firms. But due to factors like high cost of drugs and treatments along with large number of entry-to-Industry barriers, the Industry growth is feared to diminish.
Europe Industry for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the Industry is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia.
By diagnosis, the Industry is further sub-segmented into CT scan, biopsy and MRI. By treatments, the Industry is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy.
By drugs, the Industry is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic Industry owing to high prevalence rate.
Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic Industry. Gleevec was the one of the major Industry growth contributors, in the drugs category.
Geographically, Europe Industry for Leukemia Therapeutics is segmented into U.K., France, Spain, Germany, and Italy. Europe holds the second largest share in global Industry.
A number of factors such as growing awareness of leukemia screening programs, and government support are paving the way for companies to penetrate into European Leukemia Therapeutics Industry.
F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.
are the major players of Europe Leukemia Therapeutics Industry.
Key Points from Table of Contents
- Executive Summary
- Key Inferences
- New Developments
Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
Europe Leukemia Therapeutics Industry: Segmentation
- By Disease Condition
- o Chronic Lymphatic Leukemia
- o Acute Lymphatic Leukemia
- o Chronic Myeloid Leukemia
- o Acute Myeloid Leukemia
- By Diagnosis
- o CT scan
- o Biopsy
- o MRI
- By Treatments
- o Chemotherapy
- o Radiation therapy
- o Immunotherapy
- o Surgery
- o Targeted Therapy
- o Bone marrow transplant
- o Stem Cell Therapy
- By Drugs
- o Gleevec
- o Sapacitabine
- o GA101
- o Vasaroxine
- o Tosedosat
- PESTLE analysis
- Porter’s Five analysis
Industry Leaders' Analysis
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...
For more information: